GlobalMed Technologies (GMT) has acquired Omnilux Medical, the gold standard for medical and aesthetic Light Emitting Diode (LED) skincare. The asset acquisition includes three Omnilux Medical Systems, the Omnilux Revive^2™, Omnilux Blue™ and Omnilux Plus™, along with numerous patents and trademarks. 

Omnilux Medical was formerly a professional device line of PhotoMedex, Inc., a global skin health company based in Horsham, Pa. that provides medical and aesthetic solutions to dermatologists, professional aestheticians and consumers.  With the closing of the deal, GMT acquires access to an installed base of more than 3,000 Omnilux systems worldwide.

“We have sold Omnilux outside the US since 2008 and have always been enamored with its LED technology, clinical capabilities and successful outcomes in medical and aesthetic dermatology,” said Sanders Ergas, President of GlobalMed Technologies. “Recognized worldwide as a leader in light therapy, we were thrilled when we had the chance to acquire the device and add the U.S. market to our portfolio.”

Omnilux LED platform technology relies on the principle of photobiomodulation whereby cells absorb light to stimulate cellular function, leading to beneficial clinical effects. The treatment head of each Omnilux system emits light at specific, narrowband wavelengths to create a biochemical reaction of target skin cells. Depending on the matrix of LEDs, which provide different visible colors of light, Omnilux noninvasively treats a wide range of dermatologic conditions, including acne, wrinkles, pain management and non-melanoma skin cancer, among others.  There are over 30 peer-reviewed clinical studies published in highly regarded professional journals that validate Omnilux safety and efficacy. 

According to Mr. Ergas, GMT is currently considering the development of several new Omnilux applications. “We view this transaction as a growth opportunity not only for the Company but for all our clients and stakeholders.”